{"result": {"id": "5c03e746-6e18-45b2-9b25-5caffdd270d2", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>HL<|>organization<|>HL is an organization mentioned in the context of medical research and publications on hypertension and cardiovascular diseases.\")\n##\n(\"entity\"<|>MeredithPA<|>person<|>MeredithPA is a person associated with medical research, particularly in the analysis of the 'ACTION' database related to hypertension.\")\n##\n(\"entity\"<|>ACTION<|>event<|>The 'ACTION' database is referenced in research analyzing the benefits of nifedipine GITS in systolic hypertension and its combination with RAS blockade.\")\n##\n(\"entity\"<|>FurbergCD<|>person<|>FurbergCD is a researcher who contributed to studies on nifedipine and its effects on mortality in patients with coronary heart disease.\")\n##\n(\"entity\"<|>PsatyBM<|>person<|>PsatyBM is a researcher involved in studies on nifedipine and cardiovascular health.\")\n##\n(\"entity\"<|>MeyerJV<|>person<|>MeyerJV is a researcher who co-authored studies on nifedipine and its impact on coronary heart disease.\")\n##\n(\"entity\"<|>孙宁玲<|>person<|>孙宁玲 is a medical expert who contributed to the expert recommendations on the use of non-dihydropyridine calcium antagonists in cardiovascular diseases.\")\n##\n(\"entity\"<|>霍勇<|>person<|>霍勇 is a medical expert involved in the formulation of expert recommendations for cardiovascular disease treatments.\")\n##\n(\"entity\"<|>葛均波<|>person<|>葛均波 is a medical expert who co-authored recommendations on the use of non-dihydropyridine calcium antagonists in cardiovascular diseases.\")\n##\n(\"entity\"<|>中华医学会心血管病学分会<|>organization<|>中华医学会心血管病学分会 is a professional organization that publishes expert consensus on the use of ACE inhibitors in cardiovascular diseases.\")\n##\n(\"entity\"<|>中华心血管病杂志编辑委员会<|>organization<|>中华心血管病杂志编辑委员会 is an editorial board responsible for publishing expert consensus and research on cardiovascular diseases.\")\n##\n(\"entity\"<|>Danchin N<|>person<|>Danchin N is a researcher who contributed to studies on angiotensin-converting enzyme inhibitors in patients with coronary artery disease.\")\n##\n(\"entity\"<|>CucheratM<|>person<|>CucheratM is a researcher involved in studies on angiotensin-converting enzyme inhibitors and their long-term effects.\")\n##\n(\"entity\"<|>ThuillezC<|>person<|>ThuillezC is a researcher who co-authored studies on angiotensin-converting enzyme inhibitors in cardiovascular diseases.\")\n##\n(\"entity\"<|>ONTARGET Investigators<|>organization<|>ONTARGET Investigators is a research group involved in studies on telmisartan and ramipril in patients at high risk for vascular events.\")\n##\n(\"entity\"<|>YusufS<|>person<|>YusufS is a researcher associated with the ONTARGET study on telmisartan and ramipril.\")\n##\n(\"entity\"<|>TeoKK<|>person<|>TeoKK is a researcher involved in the ONTARGET study on cardiovascular treatments.\")\n##\n(\"entity\"<|>KernanWN<|>person<|>KernanWN is a researcher who contributed to guidelines for stroke prevention in patients with stroke and transient ischemic attack.\")\n##\n(\"entity\"<|>OvbiageleB<|>person<|>OvbiageleB is a researcher involved in the development of stroke prevention guidelines.\")\n##\n(\"entity\"<|>Black HR<|>person<|>Black HR is a researcher who co-authored guidelines for stroke prevention.\")\n##\n(\"entity\"<|>American Heart Association<|>organization<|>American Heart Association is a professional organization that publishes guidelines for cardiovascular health and stroke prevention.\")\n##\n(\"entity\"<|>American Stroke Association<|>organization<|>American Stroke Association is a professional organization involved in the development of stroke prevention guidelines.\")\n##\n(\"entity\"<|>Brown NJ<|>person<|>Brown NJ is a researcher who studied the association between dipeptidyl peptidase-Ⅳ inhibitors and ACE inhibitor-associated angioedema.\")\n##\n(\"entity\"<|>ByiersS<|>person<|>ByiersS is a researcher involved in studies on dipeptidyl peptidase-Ⅳ inhibitors and their side effects.\")\n##\n(\"entity\"<|>CarrD<|>person<|>CarrD is a researcher who co-authored studies on dipeptidyl peptidase-Ⅳ inhibitors.\")\n##\n(\"entity\"<|>WangJG<|>person<|>WangJG is a researcher who contributed to systematic reviews and meta-analyses on angiotensin-receptor blockers.\")\n##\n(\"entity\"<|>ZhangM<|>person<|>ZhangM is a researcher involved in studies comparing the efficacy of angiotensin-receptor blockers.\")\n##\n(\"entity\"<|>FengYQ<|>person<|>FengYQ is a researcher who co-authored meta-analyses on angiotensin-receptor blockers.\")\n##\n(\"entity\"<|>ReboldiG<|>person<|>ReboldiG is a researcher who contributed to meta-analyses comparing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.\")\n##\n(\"entity\"<|>AngeliF<|>person<|>AngeliF is a researcher involved in studies on cardiovascular treatments and meta-analyses.\")\n##\n(\"entity\"<|>CavalliniC<|>person<|>CavalliniC is a researcher who co-authored meta-analyses on cardiovascular treatments.\")\n##\n(\"entity\"<|>Parving H<|>person<|>Parving H is a researcher involved in trials of aliskiren for type 2 diabetes and its cardiorenal outcomes.\")\n##\n(\"entity\"<|>Brenner BM<|>person<|>Brenner BM is a researcher who co-authored studies on aliskiren and its effects on type 2 diabetes.\")\n##\n(\"entity\"<|>Mann JF<|>person<|>Mann JF is a researcher associated with the ONTARGET study on renal outcomes with telmisartan and ramipril.\")\n##\n(\"entity\"<|>SchmiederRE<|>person<|>SchmiederRE is a researcher involved in the ONTARGET study on cardiovascular risks and treatments.\")\n##\n(\"entity\"<|>McQueen M<|>person<|>McQueen M is a researcher who contributed to the ONTARGET study on renal outcomes.\")\n##\n(\"entity\"<|>BurnierM<|>person<|>BurnierM is a researcher who studied the redefinition of diuretics use in hypertension.\")\n##\n(\"entity\"<|>Bakris G<|>person<|>Bakris G is a researcher involved in studies on diuretics and hypertension treatments.\")\n##\n(\"entity\"<|>Williams B<|>person<|>Williams B is a researcher who co-authored studies on diuretics and hypertension.\")\n##\n(\"entity\"<|>ErnstME<|>person<|>ErnstME is a researcher who reviewed thiazide and thiazide-like diuretics in hypertension treatments.\")\n##\n(\"entity\"<|>FravelMA<|>person<|>FravelMA is a researcher involved in reviews of thiazide and thiazide-like diuretics.\")\n##\n(\"entity\"<|>WeiJ<|>person<|>WeiJ is a researcher who contributed to systematic reviews and meta-analyses on antihypertension medications.\")\n##\n(\"entity\"<|>Galaviz KI<|>person<|>Galaviz KI is a researcher involved in meta-analyses comparing cardiovascular events among different classes of antihypertension medications.\")\n##\n(\"entity\"<|>KowalskiAJ<|>person<|>KowalskiAJ is a researcher who co-authored meta-analyses on antihypertension medications.\")\n##\n(\"entity\"<|>ChalmersJ<|>person<|>ChalmersJ is a researcher who analyzed the benefits of treatment based on indapamide combined with perindopril on mortality and cardiovascular outcomes.\")\n##\n(\"entity\"<|>MouradJJ<|>person<|>MouradJJ is a researcher involved in pooled analyses of trials on indapamide and perindopril.\")\n##\n(\"entity\"<|>Brzozowska-VillatteR<|>person<|>Brzozowska-VillatteR is a researcher who co-authored analyses of trials on cardiovascular treatments.\")\n##\n(\"relationship\"<|>MeredithPA<|>ACTION<|>MeredithPA analyzed the 'ACTION' database in research on hypertension.<|>7)\n##\n(\"relationship\"<|>FurbergCD<|>PsatyBM<|>FurbergCD and PsatyBM co-authored research on nifedipine and coronary heart disease.<|>8)\n##\n(\"relationship\"<|>FurbergCD<|>MeyerJV<|>FurbergCD and MeyerJV collaborated on studies related to nifedipine.<|>8)\n##\n(\"relationship\"<|>孙宁玲<|>霍勇<|>孙宁玲 and 霍勇 co-authored expert recommendations on cardiovascular treatments.<|>8)\n##\n(\"relationship\"<|>孙宁玲<|>葛均波<|>孙宁玲 and 葛均波 collaborated on expert recommendations for cardiovascular diseases.<|>8)\n##\n(\"relationship\"<|>中华医学会心血管病学分会<|>中华心血管病杂志编辑委员会<|>Both organizations collaborated on publishing expert consensus on cardiovascular treatments.<|>9)\n##\n(\"relationship\"<|>Danchin N<|>CucheratM<|>Danchin N and CucheratM co-authored research on angiotensin-converting enzyme inhibitors.<|>8)\n##\n(\"relationship\"<|>Danchin N<|>ThuillezC<|>Danchin N and ThuillezC collaborated on studies related to coronary artery disease.<|>8)\n##\n(\"relationship\"<|>ONTARGET Investigators<|>YusufS<|>YusufS is a key researcher in the ONTARGET study.<|>9)\n##\n(\"relationship\"<|>ONTARGET Investigators<|>TeoKK<|>TeoKK contributed to the ONTARGET study on cardiovascular treatments.<|>8)\n##\n(\"relationship\"<|>KernanWN<|>OvbiageleB<|>KernanWN and OvbiageleB co-authored guidelines for stroke prevention.<|>8)\n##\n(\"relationship\"<|>KernanWN<|>Black HR<|>KernanWN and Black HR collaborated on stroke prevention guidelines.<|>8)\n##\n(\"relationship\"<|>American Heart Association<|>American Stroke Association<|>Both organizations jointly published guidelines for stroke prevention.<|>9)\n##\n(\"relationship\"<|>Brown NJ<|>ByiersS<|>Brown NJ and ByiersS co-authored research on dipeptidyl peptidase-Ⅳ inhibitors.<|>8)\n##\n(\"relationship\"<|>Brown NJ<|>CarrD<|>Brown NJ and CarrD collaborated on studies related to ACE inhibitor-associated angioedema.<|>8)\n##\n(\"relationship\"<|>WangJG<|>ZhangM<|>WangJG and ZhangM co-authored meta-analyses on angiotensin-receptor blockers.<|>8)\n##\n(\"relationship\"<|>WangJG<|>FengYQ<|>WangJG and FengYQ collaborated on systematic reviews of cardiovascular treatments.<|>8)\n##\n(\"relationship\"<|>ReboldiG<|>AngeliF<|>ReboldiG and AngeliF co-authored meta-analyses comparing cardiovascular treatments.<|>8)\n##\n(\"relationship\"<|>ReboldiG<|>CavalliniC<|>ReboldiG and CavalliniC collaborated on research related to hypertension treatments.<|>8)\n##\n(\"relationship\"<|>Parving H<|>Brenner BM<|>Parving H and Brenner BM co-authored studies on aliskiren for type 2 diabetes.<|>8)\n##\n(\"relationship\"<|>Mann JF<|>SchmiederRE<|>Mann JF and SchmiederRE collaborated on the ONTARGET study.<|>8)\n##\n(\"relationship\"<|>Mann JF<|>McQueen M<|>Mann JF and McQueen M co-authored research on renal outcomes.<|>8)\n##\n(\"relationship\"<|>BurnierM<|>Bakris G<|>BurnierM and Bakris G co-authored studies on diuretics and hypertension.<|>8)\n##\n(\"relationship\"<|>BurnierM<|>Williams B<|>BurnierM and Williams B collaborated on research related to hypertension treatments.<|>8)\n##\n(\"relationship\"<|>ErnstME<|>FravelMA<|>ErnstME and FravelMA co-authored reviews on thiazide-like diuretics.<|>8)\n##\n(\"relationship\"<|>WeiJ<|>Galaviz KI<|>WeiJ and Galaviz KI collaborated on meta-analyses of antihypertension medications.<|>8)\n##\n(\"relationship\"<|>WeiJ<|>KowalskiAJ<|>WeiJ and KowalskiAJ co-authored systematic reviews on cardiovascular events.<|>8)\n##\n(\"relationship\"<|>ChalmersJ<|>MouradJJ<|>ChalmersJ and MouradJJ co-authored pooled analyses of cardiovascular trials.<|>8)\n##\n(\"relationship\"<|>ChalmersJ<|>Brzozowska-VillatteR<|>ChalmersJ and Brzozowska-VillatteR collaborated on research related to indapamide and perindopril.<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558884, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 3017, "prompt_tokens": 2883, "total_tokens": 5900, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1091}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: HL, MeredithPA.  PreferentialbenefitsofnifedipineGITS in systolichypertension and in combination withRASblockade:  furtheranalysisofthe‘ACTION’databaseinpatientswith an- gina[J]. J Hum Hypertens,2011,25(1) :63-70.\n[247]  FurbergCD, PsatyBM, MeyerJV.  Nifedipine.  Dose-relatedin- creasein mortality in patients with coronary heartdisease[J].\n\n\n\nCirculation,1995,92(5) :1326-1331.\n[248]  孙宁玲 ,霍勇 ,葛均波 ,等.  非二氢吡啶类钙拮抗剂在心血管疾病 中应用的专家建议[J]. 中华高血压杂志 ,2015,23(3) :220-226.\n[249]  中华医学会心血管病学分会 , 中华心血管病杂志编辑委员会.  血 管紧张素转换酶抑制剂在心血管病中应用中国专家共识[J]. 中 华心血管病杂志 ,2007,35(2) :97-106.\n[250]  Danchin N, CucheratM, ThuillezC, etal. Angiotensin-conver- ting enzyme inhibitors in patients with coronary artery disease and absenceofheartfailure or left ventricular systolic dysfunc- tion: an overview oflong-term randomized controlled trials[J].   Arch Intern Med,2006,166(7) :787-796.\n[251]  ONTARGET Investigators, YusufS, TeoKK, etal. Telmisar- tan, ramipril, orbothinpatientsathighriskforvascularevents [J]. N EnglJ Med,2008,358(15) :1547-1559.\n[252]  KernanWN, OvbiageleB, Black HR, etal. Guidelines forthe prevention ofstrokeinpatientswith stroke and transientische- mic attack:  a guideline for healthcare professionals from  the American Heart Association/American Stroke Association[J].   Stroke,2014,45(7) :2160-2236.\n[253]  Brown NJ, ByiersS, CarrD, etal. Dipeptidylpeptidase-Ⅳ in- hibitoruseassociatedwithincreased risk ofACE inhibitor-asso- ciated angioedema[J]. Hypertension,2009,54(3) :516-523.\n[254]  WangJG, ZhangM, FengYQ, etal. Isthenewestangiotensin- receptorblockerazilsartan medoxomilmoreefficaciousin lower- ingblood pressurethan theolderones? A systematicreview and network meta-analysis[J]. J Clin Hypertens(Greenwich) ,2021,  23(5) :901-914.\n[255]  ReboldiG, AngeliF, CavalliniC, et al.  Comparison between angiotensin-converting enzyme inhibitors and angiotensin recep- tor blockers on the risk of myocardial infarction,  stroke and death: ameta-analysis[J]. J Hypertens,2008,26(7) :1282-1289.\n[256]  Parving H,  Brenner BM.  Cardiorenal end points in a trial of aliskiren fortype2 diabetes[J]. N EnglJ Med, 2012, 367(23) :  2204-2213.\n[257]  Mann JF, SchmiederRE, McQueen M, etal.  Renaloutcomes with telmisartan, ramipril, or both, in people athigh vascular risk (the ONTARGET  study) :  a multicentre,  randomised,  double-blind, controlledtrial[J]. Lancet, 2008, 372(9638) : 547- 553.\n[258]  BurnierM, Bakris G, Williams B.  Redefining diuretics use in hypertension: why selectathiazide-like diuretic?  [J]. J Hyper- tens,2019,37(8) :1574-1586.\n[259]  ErnstME, FravelMA.  Thiazideand thethiazide-likediuretics:  review of hydrochlorothiazide,  chlorthalidone,  and indapamide [J]. Am JHypertens,2022,35(7) :573-586.\n[260]  WeiJ, Galaviz KI, KowalskiAJ, etal.  Comparison ofcardio- vasculareventsamong usersofdifferentclassesofantihyperten- sion medications: asystematicreview andnetworkmeta-analysis [J]. JAMANetw Open,2020,3(2) :e1921618.\n[261]  ChalmersJ, MouradJJ, Brzozowska-VillatteR, etal. Benefitof treatmentbasedonindapamidemostlycombinedwithperindopril on mortality and cardiovascular outcomes: a pooled analysis of fourtrials[J]. J Hypertens,2023,41(3\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_8405031d98cfd98633319d9050d5b6c559592e901a5b948ffe1ead3b36c5d52c_v2"}